Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders
PA Thompson, CS Tam - Blood, The Journal of the American …, 2023 - ashpublications.org
Patients with lymphoproliferative disorders such as chronic lymphocytic leukemia and
mantle cell lymphoma (MCL) who are resistant to covalent Bruton tyrosine kinase inhibitors …
mantle cell lymphoma (MCL) who are resistant to covalent Bruton tyrosine kinase inhibitors …
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia
A Hatashima, M Shadman - Expert Review of Hematology, 2024 - Taylor & Francis
Introduction Bruton's tyrosine kinaseinhibitors (BTKis) changed the trajectory of upfront and
relapsed/refractory chronic lymphocytic leukemia (CLL) treatment. However, BTKis are …
relapsed/refractory chronic lymphocytic leukemia (CLL) treatment. However, BTKis are …
[HTML][HTML] Pirtobrutinib for the Treatment of B-Cell Malignancies: Recent Developments
A Schmidt - healthbook TIMES Oncology …, 2024 - onco-hema.healthbooktimes.org
Bruton tyrosine kinase (BTK) plays a vital role in B-cell functions, including differentiation,
proliferation and survival, and has emerged as a critical therapeutic target of several …
proliferation and survival, and has emerged as a critical therapeutic target of several …